A long term follow up of people who already received AAVAnc80-antiVEGF gene therapy for a vestibular schwannoma
Original title: Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
No phase is given, and this study only watches people who already got the therapy in an earlier test.
Status: Enrolling by invitation. It is only taking people the trial team invites. You cannot sign up for this one directly.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study keeps track of how people do over time after they got a gene therapy called AAVAnc80-antiVEGF.
Who this trial is for. This study is for people with a vestibular schwannoma who already received AAVAnc80-antiVEGF in an earlier trial. The therapy was given into the inner ear. This new study does not give any treatment. It follows those same people at more than one medical center.
Where it stands. The study is watching for two things over time. One is safety, meaning any problems the therapy may cause. The other is how well the therapy works. The answers are not in yet. The study has not reported results.
What this means, and what it doesn't
What it could mean: For now, this study is a way to learn what happens to people after this gene therapy. It is not open to people who did not get the therapy in the earlier trial. If you or a loved one took part in that earlier trial, your care team can tell you what follow up looks like.
What it doesn't mean: This does not mean the gene therapy works. A trial is a test, not a proven treatment. Being in a study is not a guarantee that anyone will be helped. It is not a promise of a cure. Nothing here says this therapy shrank a tumor or helped anyone's hearing, because the study has not reported that.
Source: ClinicalTrials.gov, July 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.